Berinert
Biological
CSL Behring
Total Payments
$26.5M
Transactions
766
Doctors
134
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $242,541 | 5 | 2 |
| 2023 | $655,622 | 54 | 15 |
| 2022 | $568,019 | 14 | 7 |
| 2021 | $2.6M | 300 | 60 |
| 2020 | $3.8M | 48 | 1 |
| 2019 | $3.6M | 85 | 7 |
| 2018 | $14.9M | 260 | 45 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26.3M | 344 | 99.5% |
| Honoraria | $40,890 | 11 | 0.2% |
| Travel and Lodging | $38,333 | 36 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,185 | 1 | 0.1% |
| Consulting Fee | $24,915 | 7 | 0.1% |
| Food and Beverage | $4,895 | 84 | 0.0% |
| Education | $925.29 | 283 | 0.0% |
Payments by Type
Research
$26.3M
344 transactions
General
$141,143
422 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection AMR in Adult Renal Transplant Recipients | CSL Behring | $18.5M | 0 |
| A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients | CSL Behring | $3.8M | 0 |
| A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | CSL Behring | $2.3M | 0 |
| An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | CSL Behring | $1.1M | 1 |
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 in the Prophylactic Treatment of Hereditary Angioedema | CSL Behring | $617,500 | 0 |
Top Doctors Receiving Payments for Berinert — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , AGACNP-BC | Acute Care | Fort Worth, TX | $25.65 | 1 |
| , MD | Trauma Surgery | Boca Raton, FL | $25.65 | 1 |
| , MD, MPH | Pulmonary Disease | Dallas, TX | $25.65 | 1 |
| , AGACNP-BC | Acute Care | Richardson, TX | $25.65 | 1 |
| , PA-C | Medical | Garland, TX | $25.65 | 1 |
| Erin Wolf | Acute Care | Dallas, TX | $25.65 | 1 |
| , M.D | Internal Medicine | Springfield, MO | $24.75 | 15 |
| , M.D | Pediatric Allergy/Immunology | Rogers, AR | $24.62 | 16 |
| , B.S., M.D | Allergy | Rogers, AR | $22.49 | 16 |
| , MD | Emergency Medicine | Atmore, AL | $19.88 | 1 |
| , MD | Hospitalist | Mobile, AL | $19.88 | 1 |
| , D.O | Allergy & Immunology | Kirksville, MO | $19.67 | 13 |
| , MD | Internal Medicine | Dothan, AL | $18.89 | 1 |
| , MD | Internal Medicine | Tallahassee, FL | $18.89 | 1 |
| , DO | Internal Medicine | Dothan, AL | $18.89 | 1 |
| , M.D | Emergency Medicine | Phoenix, AZ | $17.30 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Phoenix, AZ | $17.30 | 1 |
| , M.D | Allergy | Warrensburg, MO | $17.26 | 11 |
| , M.D | Pulmonary Disease | Lubbock, TX | $17.14 | 1 |
| , DO | Student in an Organized Health Care Education/Training Program | Lubbock, TX | $17.14 | 1 |
| , M.D | Pulmonary Disease | La Jolla, CA | $17.13 | 1 |
| , M.D | Internal Medicine | Lubbock, TX | $17.13 | 1 |
| , M.D | Pulmonary Disease | Lubbock, TX | $17.13 | 1 |
| , MD | Emergency Medicine | Morristown, NJ | $16.96 | 1 |
| , D.O | Emergency Medicine | Morristown, NJ | $16.96 | 1 |
Ad
Manufacturing Companies
- CSL Behring $26.5M
Product Information
- Type Biological
- Total Payments $26.5M
- Total Doctors 134
- Transactions 766
About Berinert
Berinert is a biological associated with $26.5M in payments to 134 healthcare providers, recorded across 766 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2018 to 2024. In 2024, $242,541 was paid across 5 transactions to 2 doctors.
The most common payment nature for Berinert is "Unspecified" ($26.3M, 99.5% of total).
Berinert is associated with 5 research studies, including "Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection AMR in Adult Renal Transplant Recipients" ($18.5M).